Dry Powder Inhalers (DPI)

A dry powder inhaled liposomal azithromycin formulation was developed for the treatment of chronic respiratory diseases such as cystic fibrosis...

Pulmonary inflammations such as chronic obstructive pulmonary disease and cystic fibrosis are widespread and can be fatal, especially when they...

Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are versatile means for the highly efficient delivery of...

Abstract In this review, an extensive analysis of dry powder inhalers (DPIs) is offered, focusing on their characteristics, formulation, stability,...

Cystic fibrosis (CF) is an inherited lung disease characterised by the accumulation of thick layers of dried mucus in the...

Abstract Pulmonary delivery of protein-based therapeutics, including antibodies, is a promising option for treating respiratory diseases. Spray drying is a...

Abstract Objectives The aim of the project was to develop and characterise powders containing a probiotic (Lactiplantibacillus plantarum , Lacticaseibacillus rhamnosus,...

Wasserburg, Germany, December, 2023: Pharmaceutical lactose specialist MEGGLE will use the Drug Delivery to the Lungs (DDL) Conference in Edinburgh,...

Abstract Although the amount of amorphous content in lactose is low, its impact on the performance of a dry powder...

The supercritical antisolvent-fluidized bed coating process (SAS-FB) shows great potential as a technique to manufacture dry powder inhaler (DPI) that...